Drugs / ABBV-744
ABBV-744
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04454658 | Nov 2020 → Jan 2027 expected | myelofibrosis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03360006 | Mar 2018 → Dec 2020 | acute myeloid leukemia | AbbVie | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-744 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03360006 ↗ |
| Known as | N-ETHYL-4-[2-(4-FLUORO-2,6-DIMETHYLPHENOXY)-5-(2-HYDROXYPROPAN-2-YL)PHENYL]-6-METHYL-7-OXO-1H,6H,7H-PYRROLO[2,3-C]PYRIDINE-2-CARBOXAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297454 ↗ |
| Action | Inhibit | “ABBV-744 is a highly selective inhibitor for the second bromodomain of the four BET family proteins.” PMID 34253595 ↗ Jul 2021 |
| Modality | Small molecule | “ABBV-744 is a novel small molecule that targets the BDII of BET proteins” PMID 41843794 ↗ May 2026 |
| Route | Oral | “Tablet, oral” NCT03360006 ↗ |